Spyridon Siafis

List of Publications by Year
in descending order

46 papers	1,099 citations	567281 15 h-index	454955 30 g-index
47 all docs	47 docs citations	47 times ranked	898 citing authors

#	Article	IF	Citations
1	Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia. American Journal of Psychiatry, 2020, 177, 342-353.	7.2	137
2	Psychosocial and psychological interventions for relapse prevention in schizophrenia: a systematic review and network meta-analysis. Lancet Psychiatry,the, 2021, 8, 969-980.	7.4	114
3	Antipsychotic Drugs: From Receptor-binding Profiles to Metabolic Side Effects. Current Neuropharmacology, 2018, 16, 1210-1223.	2.9	98
4	Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis. Lancet, The, 2022, 399, 824-836.	13.7	88
5	Efficacy and safety of clozapine in psychotic disordersâ€"a systematic quantitative meta-review. Translational Psychiatry, 2021, 11, 487.	4.8	61
6	Maintenance treatment with antipsychotic drugs for schizophrenia. The Cochrane Library, 2020, 2020, CD008016.	2.8	56
7	Family interventions for relapse prevention in schizophrenia: a systematic review and network meta-analysis. Lancet Psychiatry,the, 2022, 9, 211-221.	7.4	47
8	Examination of Dosing of Antipsychotic Drugs for Relapse Prevention in Patients With Stable Schizophrenia. JAMA Psychiatry, 2021, 78, 1238.	11.0	44
9	Placebo response in pharmacological and dietary supplement trials of autism spectrum disorder (ASD): systematic review and meta-regression analysis. Molecular Autism, 2020, 11, 66.	4.9	40
10	Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis. Molecular Autism, 2022, 13, 10.	4.9	36
11	Antipsychotic-Induced Weight Gain: Dose-Response Meta-Analysis of Randomized Controlled Trials. Schizophrenia Bulletin, 2022, 48, 643-654.	4.3	35
12	Detecting a potential safety signal of antidepressants and type 2 diabetes: a pharmacovigilanceâ€pharmacodynamic study. British Journal of Clinical Pharmacology, 2018, 84, 2405-2414.	2.4	30
13	A white paper on a neurodevelopmental framework for drug discovery in autism and other neurodevelopmental disorders. European Neuropsychopharmacology, 2021, 48, 49-88.	0.7	29
14	Prevalence of Cannabis Use Among Medical Students: A Systematic Review and Meta-analysis. Substance Abuse: Research and Treatment, 2018, 12, 117822181880597.	0.9	27
15	Nogo receptor complex expression dynamics in the inflammatory foci of central nervous system experimental autoimmune demyelination. Journal of Neuroinflammation, 2016, 13, 265.	7.2	24
16	Prolactin levels influenced by antipsychotic drugs in schizophrenia: A systematic review and network meta-analysis. Schizophrenia Research, 2021, 237, 20-25.	2.0	22
17	Antidepressants on Multiple Sclerosis: A Review of In Vitro and In Vivo Models. Frontiers in Immunology, 2021, 12, 677879.	4.8	20
18	Second-to-Fourth Digit Ratio (2D:4D) in Psychiatric Disorders: A Systematic Review of Case-control Studies. Clinical Psychopharmacology and Neuroscience, 2021, 19, 26-45.	2.0	17

#	Article	IF	Citations
19	Disease–modifying agents for multiple sclerosis and the risk for reporting cancer: A disproportionality analysis using the US Food and Drug Administration Adverse Event Reporting System database. British Journal of Clinical Pharmacology, 2021, 87, 4769-4779.	2.4	16
20	Adverse events after antipsychotic discontinuation: an individual participant data meta-analysis. Lancet Psychiatry,the, 2022, 9, 232-242.	7.4	15
21	The Administrative Prevalence of Multiple Sclerosis in Greece on the Basis of a Nationwide Prescription Database. Frontiers in Neurology, 2020, 11, 1012.	2.4	14
22	Maintenance Treatment With Antipsychotic Drugs in Schizophrenia: A Cochrane Systematic Review and Meta-analysis. Schizophrenia Bulletin, 2022, 48, 738-740.	4.3	13
23	Nonmedical Use of Prescription Drugs among Medical Students and the Relationship With Illicit Drug, Tobacco, and Alcohol Use. Substance Abuse: Research and Treatment, 2018, 12, 117822181880229.	0.9	11
24	Safety of antipsychotic drugs: A systematic review of disproportionality analysis studies. Behavioural Brain Research, 2021, 404, 113168.	2.2	11
25	Antipsychotic drugs: from 'major tranquilizers' to Neuroscience-based-Nomenclature. Psychological Medicine, 2021, 51, 522-524.	4.5	10
26	Assessment of the Safety Signal for the Abuse Potential of Pregabalin and Gabapentin Using the FAERS Database and Big Data Search Analytics. Frontiers in Psychiatry, 2021, 12, 640264.	2.6	9
27	Shared decision making, aggression, and coercion in inpatients with schizophrenia. European Psychiatry, 2020, 63, e90.	0.2	7
28	Combining big data search analytics and the FDA Adverse Event Reporting System database to detect a potential safety signal of mirtazapine abuse. Health Informatics Journal, 2020, 26, 2265-2279.	2.1	7
29	Short-acting intramuscular second-generation antipsychotic drugs for acutely agitated patients with schizophrenia spectrum disorders. A systematic review and network meta-analysis. Schizophrenia Research, 2021, 229, 3-11.	2.0	7
30	How Efficacious Are Antipsychotic Drugs for Schizophrenia? An Interpretation Based on 13 Effect Size Indices. Schizophrenia Bulletin, 2022, 48, 27-36.	4.3	7
31	Antipsychotic drugs *v.* barbiturates or benzodiazepines used as active placebos for schizophrenia: a systematic review and meta-analysis. Psychological Medicine, 2020, 50, 2622-2633.	4.5	6
32	Levetiracetam as preventive treatment in adults with migraine: an up-to-date systematic review and quantitative meta-analysis. European Journal of Clinical Pharmacology, 2020, 76, 161-174.	1.9	6
33	The Added Value of Liquid Antipsychotics: The Case of Quetiapine. Current Clinical Pharmacology, 2019, 14, 101-107.	0.6	5
34	Metabolic side effects of antipsychotic drugs in individuals with schizophrenia during medium- to long-term treatment: protocol for a systematic review and network meta-analysis of randomized controlled trials. Systematic Reviews, 2021, 10, 214.	5.3	5
35	Safety profile of chloroquine and hydroxychloroquine: a disproportionality analysis of the FDA Adverse Event Reporting System database. European Review for Medical and Pharmacological Sciences, 2021, 25, 6003-6012.	0.7	5
36	Exploring a Safety Signal of Antipsychotic-Associated Pneumonia: A Pharmacovigilance-Pharmacodynamic Study. Schizophrenia Bulletin, 2021, 47, 672-681.	4.3	4

#	Article	IF	Citations
37	Imputing the Number of Responders from the Mean and Standard Deviation of CGI-Improvement in Clinical Trials Investigating Medications for Autism Spectrum Disorder. Brain Sciences, 2021, 11, 908.	2.3	4
38	Atypical antipsychotics in multiple sclerosis: A review of their in vivo immunomodulatory effects. Multiple Sclerosis and Related Disorders, 2022, 58, 103522.	2.0	4
39	The Effects of PDE Inhibitors on Multiple Sclerosis: a Review of in vitro and in vivo Models. Current Pharmaceutical Design, 2021, 27, 2387-2397.	1.9	3
40	Tachyphylaxis to the Sedative Action of Mirtazapine. American Journal of Case Reports, 2018, 19, 410-412.	0.8	2
41	Evidence-based Shared-Decision-Making Assistant (SDM-assistant) for choosing antipsychotics: protocol of a cluster-randomized trial in hospitalized patients with schizophrenia. BMC Psychiatry, 2022, 22, .	2.6	2
42	Validation of the Glasgow Antipsychotic Side-Effect Scale (GASS) in an Italian Sample of Patients with Stable Schizophrenia and Bipolar Spectrum Disorders. Brain Sciences, 2022, 12, 891.	2.3	1
43	M201. MODERATORS OF WEIGHT GAIN IN RANDOMIZED CONTROLLED TRIALS OF SCHIZOPHRENIA â€" A META-REGRESSION ANALYSIS. Schizophrenia Bulletin, 2020, 46, S212-S213.	4.3	0
44	T200. METABOLIC SIDE EFFECTS OF ANTIPSYCHOTIC DRUGS â€" PROTOCOL OF A SYSTEMATIC REVIEW AND NETWORK- METAANALYSIS. Schizophrenia Bulletin, 2020, 46, S308-S308.	4.3	0
45	Limitations in Research on Maintenance Treatment for Individuals With Schizophreniaâ€"Reply. JAMA Psychiatry, 2021, , .	11.0	0
46	Confidence of evidence should be considered in ranking of treatments in the network meta-analysis â€" Authors' reply. Lancet Psychiatry,the, 2022, 9, e16.	7.4	0